ISM3412

Asset

Oral MAT2A inhibitor, synthetically lethal in cancers that have lost MTAP

Stage
Phase 1
Modality
Small molecule
Target
MAT2A
1
Indication
1
Trial
1
Developer

Indications

1

In the full profile

  • Targets and what it contains1
  • Owner and partners1
  • Trials1
  • Evidence for its targets1
  • Competitors1
  • Signals1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets